Medical Information
United States

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

PREMARIN® VAGINAL CREAM Adverse Reactions (conjugated estrogens)


The following serious adverse reactions are discussed elsewhere in the labeling:

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In a 12-week, randomized, double-blind, placebo-controlled trial of PREMARIN Vaginal Cream (PVC), a total of 423 postmenopausal women received at least 1 dose of study medication and were included in all safety analyses: 143 women in the PVC-21/7 treatment group (0.5 g PVC daily for 21 days, then 7 days off), 72 women in the matching placebo treatment group; 140 women in the PVC-2×/wk treatment group (0.5 g PVC twice weekly), 68 women in the matching placebo treatment group. A 40-week, open-label extension followed, in which a total of 394 women received treatment with PVC, including those subjects randomized at baseline to placebo. In this study, the most common adverse reactions ≥ 1 percent in the double blind phase are shown below (Table 1) [see Clinical Studies (14.1)].

Table 1: Number (%) of Patients Reporting Treatment Emergent Adverse Reactions ≥ 1 Percent Only
Body System*/Adverse ReactionPVC 21/7

Placebo 21/7

PVC 2×/week

Placebo 2×/week
Number (%) of Patients with Adverse Reaction
Body system totals are not necessarily the sum of individual adverse events, since a patient may report two or more different adverse reactions in the same body system.
Body As A Whole
Abdominal Pain1 (0.7)1 (1.4)01 (1.5)
Headache5 (3.5)1 (1.4)3 (2.1)1 (1.5)
Moniliasis2 (1.4)1 (1.4)1 (0.7)0
Pain2 (1.4)01 (0.7)0
Pelvic Pain4 (2.8)2 (2.8)4 (2.9)0
Cardiovascular System
Migraine0001 (1.5)
Vasodilation3 (2.1)2 (2.8)2 (1.4)0
Musculoskeletal System
Muscle Cramp2 (1.4)000
Nervous System
Dizziness1 (0.7)001 (1.5)
Skin and Appendages
Acne002 (1.4)0
Erythema01 (1.4)00
Pruritus2 (1.4)1 (1.4)1 (0.7)0
Urogenital System
Breast Enlargement1 (0.7)1 (1.4)00
Breast Pain7 (4.9)03 (2.1)0
Dysuria2 (1.4)000
Leukorrhea3 (2.1)1 (1.4)4 (2.9)5 (7.4)
Metrorrhagia0002 (2.9)
Urinary Frequency01 (1.4)00
Urinary Tract Infection01 (1.4)00
Urinary Urgency1 (0.7)1 (1.4)00
Vaginal Hemorrhage2 (1.4)01 (0.7)1 (1.5)
Vaginal Moniliasis2 (1.4)000
Vaginitis2 (1.4)1 (1.4)3 (2.1)3 (4.4)
Vulvovaginal Disorder4 (2.8)03 (2.1)2 (2.9)

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of PREMARIN Vaginal Cream. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Genitourinary System

Abnormal uterine bleeding or spotting, dysmenorrhea or pelvic pain, increase in size of uterine leiomyomata, vaginitis (including vaginal candidiasis), change in cervical secretion, cystitis-like syndrome, application site reactions of vulvovaginal discomfort, (including burning, irritation, and genital pruritus), endometrial hyperplasia, endometrial cancer, precocious puberty, leukorrhea.


Tenderness, enlargement, pain, discharge, fibrocystic breast changes, breast cancer, gynecomastia in males.


Deep venous thrombosis, pulmonary embolism, myocardial infarction, stroke, increase in blood pressure.


Nausea, vomiting, abdominal cramps, bloating, increased incidence of gallbladder disease.


Chloasma that may persist when drug is discontinued, loss of scalp hair, hirsutism, rash.


Retinal vascular thrombosis, intolerance to contact lenses.

Central Nervous System

Headache, migraine, dizziness, mental depression, nervousness, mood disturbances, irritability, dementia.


Increase or decrease in weight, glucose intolerance, edema, arthralgias, leg cramps, changes in libido, urticaria, exacerbation of asthma, increased triglycerides, hypersensitivity.

Additional postmarketing adverse reactions have been reported in patients receiving other forms of hormone therapy.

Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event